Chemical Aversive Conditioning for Alcoholism — CPB 0896 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0896 — its chemical aversive conditioning for alcoholism coverage policy — effective January 5, 2026. Aetna classifies this treatment as experimental, investigational, or unproven. Claims billed under F10.10–F10.29 for this service will be denied.

Aetna Chemical Aversive Conditioning Coverage Policy: Medical Necessity Requirements 2026

The Aetna chemical aversive conditioning coverage policy under CPB 0896 in the Aetna system is direct: there is no covered indication for this treatment. Aetna does not recognize chemical aversive conditioning for alcoholism as medically necessary. If your team has been billing this service for Aetna members, you should expect a claim denial — not a request for more documentation.

This matters because behavioral health billing teams sometimes assume that any active treatment for alcohol use disorder carries at least a pathway to coverage. That assumption does not hold here. Aetna's position under CPB 0896 is categorical. The payer considers this treatment unproven, full stop.

The effective date of January 5, 2026, means this modified policy is already active. If you haven't reviewed your charge capture and denial management workflows for Aetna members receiving addiction treatment, do it now.

Prior authorization won't help here. There is no prior authorization pathway that unlocks coverage for this service under this policy. Requesting prior auth for chemical aversive conditioning on an Aetna plan is not a viable billing strategy — it will not result in reimbursement.

Aetna Chemical Aversive Conditioning Exclusions and Non-Covered Indications

Aetna classifies chemical aversive conditioning for alcoholism as experimental, investigational, or unproven. That classification carries real weight in Aetna's adjudication system. It means the payer has reviewed the evidence base and concluded it does not support coverage.

The diagnosis codes that apply here span the full F10.1x and F10.2x ranges — from alcohol abuse (F10.10 through F10.19) to alcohol dependence (F10.20 through F10.29). None of these diagnoses create a covered indication for this treatment. The diagnosis doesn't change the outcome. The service itself is what's excluded.

This is the same pattern you see across Aetna's experimental-designation policies. Once a treatment hits that classification, it doesn't matter how the claim is coded or what documentation supports it. The denial is upstream of coding. Your billing team can code a claim perfectly and still get denied — because the coverage policy prohibits the service, not because documentation was insufficient.

If your practice is actively offering chemical aversive conditioning to Aetna members and billing for it, talk to your compliance officer before your next claim drops. There may be patient financial responsibility and consent implications beyond the denial itself.

Coverage Indications at a Glance

Aetna Chemical Aversive Conditioning Billing Guidelines and Action Items 2026

The policy has been active since January 5, 2026. Here's what your billing team needs to do now.

CPT, HCPCS, and ICD-10 Codes for Chemical Aversive Conditioning Under CPB 0896

The policy data for CPB 0896 does not list specific CPT or HCPCS procedure codes for chemical aversive conditioning. Aetna's experimental designation applies to the treatment category itself. The relevant codes provided in this policy are all ICD-10-CM diagnosis codes covering alcohol abuse and alcohol dependence.

Key ICD-10-CM Diagnosis Codes

All 20 codes listed under CPB 0896 fall into two categories: alcohol abuse (F10.1x) and alcohol dependence (F10.2x). The full list is below.

These codes identify the patient population affected by this coverage policy. None of them create a path to reimbursement for chemical aversive conditioning under Aetna. They are the diagnosis codes your team would attach to any addiction treatment claim for these patients — and CPB 0896 says that when those claims are for chemical aversive conditioning, Aetna will not pay.

One practical note on coding specificity: the F10.1x and F10.2x ranges include subcodes that differentiate by clinical features — uncomplicated, with intoxication, with withdrawal, with perceptual disturbance, and others. Aetna's experimental designation under CPB 0896 covers the entire range. There is no subcode within these ranges that creates a covered indication. Chemical aversive conditioning billing guidelines for Aetna do not vary by the specific subcode used.